Newsfeeds - Spark Newswire

1 minute read

Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs

Today, 3:55 PM

Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334).

ASMB

13 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 3:55 PM

Wednesday saw 219 companies set new 52-week lows.

$APE

1 minute read

Mizuho Maintains Buy on Assembly Biosciences, Lowers Price Target to $3

By Benzinga Newsdesk

Today, 3:55 PM

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $14 to $3.

ASMB

4 minute read

Assembly Bio Announces Retirement Of John G. McHutchison As CEO And Appoints Current President And COO Jason A. Okazaki As Successor

By Benzinga Newsdesk

Today, 3:55 PM

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B

ASMB

3 minute read

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners

By Vandana Singh

Today, 3:55 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection

By Vandana Singh

Today, 3:55 PM

Assembly Biosciences Inc (NASDAQ:ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core…

ASMB